KR20230163500A - 면역원성 융합 단백질 - Google Patents

면역원성 융합 단백질 Download PDF

Info

Publication number
KR20230163500A
KR20230163500A KR1020237037124A KR20237037124A KR20230163500A KR 20230163500 A KR20230163500 A KR 20230163500A KR 1020237037124 A KR1020237037124 A KR 1020237037124A KR 20237037124 A KR20237037124 A KR 20237037124A KR 20230163500 A KR20230163500 A KR 20230163500A
Authority
KR
South Korea
Prior art keywords
fusion protein
amino acid
acid sequence
seq
immunogenic fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237037124A
Other languages
English (en)
Korean (ko)
Inventor
피셔 페르 보 페덜슨
Original Assignee
미네르박스 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미네르박스 에이피에스 filed Critical 미네르박스 에이피에스
Publication of KR20230163500A publication Critical patent/KR20230163500A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237037124A 2021-03-29 2022-03-29 면역원성 융합 단백질 Pending KR20230163500A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21165674.9 2021-03-29
EP21165674.9A EP4066854A1 (en) 2021-03-29 2021-03-29 Immunogenic fusion protein
PCT/EP2022/058309 WO2022207657A1 (en) 2021-03-29 2022-03-29 Immunogenic fusion protein

Publications (1)

Publication Number Publication Date
KR20230163500A true KR20230163500A (ko) 2023-11-30

Family

ID=75277909

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237037124A Pending KR20230163500A (ko) 2021-03-29 2022-03-29 면역원성 융합 단백질

Country Status (12)

Country Link
US (1) US20240173394A1 (https=)
EP (2) EP4066854A1 (https=)
JP (1) JP2024512722A (https=)
KR (1) KR20230163500A (https=)
CN (1) CN117120081A (https=)
AU (1) AU2022248869A1 (https=)
BR (1) BR112023019757A2 (https=)
CA (1) CA3212987A1 (https=)
IL (1) IL307256A (https=)
MX (1) MX2023011502A (https=)
WO (1) WO2022207657A1 (https=)
ZA (1) ZA202309225B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4553166A1 (en) 2023-11-07 2025-05-14 MinervaX ApS Method for preparing a sample for analysis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107458A0 (en) 1992-11-02 1994-02-27 Gen Hospital Corp Conjugate vaccine against group b streptococcus
HU217582B (hu) 1993-03-19 2000-02-28 Gunnar Lindahl Streptococcus B csoportba tartozó törzsek elleni immunitást biztosító, Rib fehérjenevű felületi protein, eljárás a protein tisztítására, reagenskészlet és gyógyszerkészítmény
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
SI2144924T1 (sl) * 2007-04-16 2016-12-30 Minervax Aps Cepivo s fuzijskimi beljakovinami
CN108135992A (zh) * 2015-10-21 2018-06-08 米纳瓦克斯有限责任公司 免疫原性融合蛋白
US10888610B2 (en) * 2015-12-30 2021-01-12 Minerv Ax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus

Also Published As

Publication number Publication date
EP4313134A1 (en) 2024-02-07
MX2023011502A (es) 2023-10-19
CA3212987A1 (en) 2022-10-06
AU2022248869A9 (en) 2023-11-09
US20240173394A1 (en) 2024-05-30
JP2024512722A (ja) 2024-03-19
AU2022248869A1 (en) 2023-10-26
BR112023019757A2 (pt) 2023-10-31
EP4066854A1 (en) 2022-10-05
IL307256A (en) 2023-11-01
ZA202309225B (en) 2025-03-26
CN117120081A (zh) 2023-11-24
WO2022207657A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
US12173033B2 (en) Immunogenic fusion protein
RU2487890C2 (ru) Слитый белок, способный индуцировать защитный иммунитет против стрептококка группы в, и вакцина, содержащая такой белок
US11484584B2 (en) Immunogenic complex for eliciting protective immunity against group B Streptococcus
KR20110061586A (ko) Ｐ．진지발리스 감염의 예방, 치료 및 진단
JP2020502075A (ja) 肺炎球菌表面プロテインａの選択されたアルファヘリカルドメインおよびプロリンリッチドメインを組み合わせた肺炎球菌ワクチン
KR20230163500A (ko) 면역원성 융합 단백질
KR102675880B1 (ko) SARS-CoV-2 스파이크 단백질 및 면역글로불린의 Fc 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
US7255867B2 (en) Vaccine
OA21833A (en) Immunogenic fusion protein.
EA051105B1 (ru) Иммуногенный слитый белок
HK1250933A1 (en) Immunogenic fusion protein
AU2024337266A1 (en) Products and methods for inducing immune responses to bacteria

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000